| First Author | Zhou L | Year | 2023 |
| Journal | Cell Rep | Volume | 42 |
| Issue | 5 | Pages | 112445 |
| PubMed ID | 37141098 | Mgi Jnum | J:336654 |
| Mgi Id | MGI:7491458 | Doi | 10.1016/j.celrep.2023.112445 |
| Citation | Zhou L, et al. (2023) DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90beta. Cell Rep 42(5):112445 |
| abstractText | The molecular and pathogenic mechanisms of esophageal squamous cell carcinoma (ESCC) development are still unclear, which hinders the development of effective treatments. In this study, we report that DUSP4 is highly expressed in human ESCC and is negatively correlated with patient prognosis. Knockdown of DUSP4 suppresses cell proliferation and patient-derived xenograft (PDX)-derived organoid (PDXO) growth and inhibits cell-derived xenograft (CDX) development. Mechanistically, DUSP4 directly binds to heat shock protein isoform beta (HSP90beta) and promotes the ATPase activity of HSP90beta by dephosphorylating HSP90beta on T214 and Y216. These dephosphorylation sites are critical for the stability of JAK1/2-STAT3 signaling and p-STAT3 (Y705) nucleus translocation. In vivo, Dusp4 knockout in mice significantly inhibits 4-nitrochinoline-oxide-induced esophageal tumorigenesis. Moreover, DUSP4 lentivirus or treatment with HSP90beta inhibitor (NVP-BEP800) significantly impedes PDX tumor growth and inactivates the JAK1/2-STAT3 signaling pathway. These data provide insight into the role of the DUSP4-HSP90beta-JAK1/2-STAT3 axis in ESCC progression and describe a strategy for ESCC treatment. |
